Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Eir
  6. /
  7. Bioreliance Corporation
EIR
•Bioreliance Corporation•July 13, 2018

Bioreliance Corporation – FDA EIR, Jul 13, 2018

Record Details

A U.S. Food and Drug Administration (FDA) inspection was conducted at BioReliance Corporation's Rockville, MD facility from July 9-13, 2018. The inspection, part of the Team Biologics FY 2018 work plan, focused on the company's role as a contract testing laboratory for pharmaceutical and biologics industries, under compliance programs for biological drug products. Following the five-day assessment, the FDA issued a two-item Form 483, detailing significant observations requiring corrective action. The inspection identified two main areas of concern. Firstly, the firm's data integrity practices for electronic records were deemed insufficient. Backup data was not adequately assured for completeness or security against alteration, erasure, or loss. Furthermore, electronic records did not meet operational system checks to ensure their trustworthiness and reliability. Specifically, the Quality Unit

s internal audit procedure lacked defined frequencies for auditing critical systems and a validated method for sampling long-term archived electronic records. The electronic records retention procedure also failed to detail how corrupted or missing archived data should be managed. Secondly, the Quality Unit demonstrated a systemic failure in the timely review and approval of change controls. This resulted in numerous general change control records, some related to the installation of new laboratory equipment or system updates, remaining open for over two years, hindering timely closure. Management acknowledged the necessity to strengthen their change control program as an area of focus. The issuance of the FDA 483 mandates BioReliance to formally address these observations with the agency.

Company
Bioreliance Corporation
Inspection date
July 13, 2018
Product type
biologics
Office
Baltimore District Office
Person
  • Susan M. Jackson (investigator)
View Company Profile

ID · 4b7d144e-2850-4fc9-8a87-54e30822e3c8

Other documents for Bioreliance Corporation
  • 483 - 2026-01-29January 29, 2026
  • 483 - 2024-11-22November 22, 2024
  • EIR - 2019-08-08August 8, 2019
  • EIR - 2008-09-29September 29, 2008
  • 483

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bioreliance Corporation
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.